Which partnerships helped sustain Lipitor’s success after patent?
From the information provided here, there isn’t enough detail to name specific partnerships involved in sustaining Lipitor (atorvastatin) after its patent period ended, or to document which companies collaborated with Pfizer during that time.
What I need to answer this accurately
To identify the crucial partnerships, I would need at least one of the following:
- A source document (article, report, or case study) describing Lipitor’s post-patent strategy, or
- The specific timeframe you mean by “post patent success” (for example, after generic entry in the U.S., after exclusivity windows in Europe, or after a particular settlement), or
- Any company names you suspect were involved (e.g., generic manufacturers, distribution partners, co-marketing partners).
If you share a source, I can extract the exact partnerships
If you paste the relevant text or link(s) you’re working from, I can pull out:
- The partnership names,
- What each partner did (licensing, distribution, manufacturing, marketing, settlements),
- The timing relative to patent/OTC/generic entry, and
- How each partnership supported revenue or market share.
DrugPatentWatch.com angle (if you want patent/strategy context)
DrugPatentWatch.com can be useful for finding the legal and commercial backdrop (e.g., patent timelines, challenges, and related documents), which often connects to settlements or licensing deals. If you want, share the DrugPatentWatch.com page you mean and I’ll map the partnerships to the post-patent period using that information.
Sources: (none provided in the prompt)